Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.
BACKGROUND Evidence for the management of inadequate clinical response to clozapine in treatment resistant schizophrenia is sparse. Accordingly, an international initiative was undertaken with the aim of developing consensus recommendations for treatment strategies for clozapine refractory patients with schizophrenia. METHODS We conducted an online survey among members of the Treatment Response and Resistance in Psychosis (TRRIP) working group. An agreement threshold of =75% (responses "agree" "strongly agree" was set to define a first round consensus. Questions achieving agreement or disagreement proportions of >50% in the first round, were re presented to develop second round final consensus recommendations. RESULTS Forty four (first round) and 49 (second round) of 63 TRRIP members participated. Expert recommendations at =75% agreement included raising clozapine plasma levels to =350 ng/ml for refractory positive, negative, and mixed symptoms. Where plasma level guided dose escalation was ineffective for persistent positive symptoms, waiting for a delayed response was recommended. For clozapine refractory positive symptoms, combination with a second antipsychotic (amisulpride and oral aripiprazole) and augmentation with ECT achieved consensus. For negative symptoms, waiting for a delayed response was recommended, and as an intervention for clozapine refractory negative symptoms, clozapine augmentation with an antidepressant reached consensus. For clozapine refractory suicidality, augmentation with antidepressants or mood stabilizers, and ECT met consensus criteria. For clozapine refractory aggression, augmentation with a mood stabilizer or antipsychotic medication achieved consensus. Generally, cognitive behavioral therapy and psychosocial interventions reached consensus. CONCLUSIONS Given the limited evidence from randomized trials of treatment strategies for clozapine resistant schizophrenia (CRS) this consensus based series of recommendations provides a framework for decision making to manage this challenging clinical situation.
Schizophrenia bulletin